Phenotyping bleeding

Current Opinion in Hematology

Volumn 19, Issue 5, 2012, Pages 406-412

  James, Paula ^a   Coller, Barry S ^b  

^a QUEEN S UNIVERSITY   (Canada)

^b ROCKEFELLER UNIVERSITY   (United States)

Author keywords

bleeding; immune thrombocytopenia; percutaneous coronary intervention; phenotyping; von Willebrand disease

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; APROTININ; DABIGATRAN; ELTROMBOPAG; THROMBOPOIETIN; TRANEXAMIC ACID; WARFARIN;

ANTICOAGULATION; AUTOIMMUNE THROMBOCYTOPENIA; BLEEDING; BLEEDING DISORDER; CORONARY ARTERY BYPASS GRAFT; DRUG EFFICACY; GENOTYPE; GENOTYPE ENVIRONMENT INTERACTION; HEART ATRIUM FIBRILLATION; HEART SURGERY; HIGH RISK PATIENT; HUMAN; INVASIVE PROCEDURE; LABORATORY TEST; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PHENOTYPE; POSTOPERATIVE HEMORRHAGE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK ASSESSMENT; RISK FACTOR; STANDARDIZATION; SURGICAL RISK; THROMBOCYTOPOIESIS; VALIDATION PROCESS; VON WILLEBRAND DISEASE;

ADMINISTRATION, ORAL; ANTICOAGULANTS; GENE-ENVIRONMENT INTERACTION; GENOTYPE; HEMORRHAGIC DISORDERS; HUMANS; PHENOTYPE; PREDICTIVE VALUE OF TESTS;

EID: 84865443895     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0b013e32835673ab     Document Type: Review

References (56)

1. Rosner F. Hemophilia in the Talmud and rabbinic writings. Ann Intern Med 1969; 70:833-837.
2. Kaadan AN, Angrini M. Who discovered hemophilia? J Int Soc History Islamic Med 2009; 8-9:46-50.
3. Bullock W, Fildes P. Treasury of human inheritance. Haemophilia. London: Dulau and Co. Ltd; 1911.
4. Otto JC. An account of an hemorrhagic disposition existing in certain families. Clin Orthop Relat Res 1996;(328):4-6.
5. Coller BS, Schneiderman PI. Clinical evaluation of hemorrhagic disorders: The bleeding history and differential diagnosis of purpura. In: Hoffman R, Benz EJ, Shattil SJ, et al., editors. Hematology: Basic principles and practice. 5th ed. New York: Churchill Livingstone; 2008. pp. 1851-1876.
6. Chee YL, Crawford JC, Watson HG, et al. Guidelines on the assessment of bleeding risk prior to surgery or invasive procedures. British Committee for Standards in Haematology. Br J Haematol 2008; 140:496-504. (Pubitemid 351230081)
7. Eckman MH, Erban JK, Singh SK, et al. Screening for the risk for bleeding or thrombosis. Ann Intern Med 2003; 138:W15-W24.
8. Rodeghiero F, Castaman G, Tosetto A, et al. The discriminant power of bleeding history for the diagnosis of type 1 von Willebrand disease: an international, multicenter study. J Thromb Haemost 2005; 3:2619-2626. (Pubitemid 41819788)
9. Tosetto A, Rodeghiero F, Castaman G, et al. A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1 VWD). J Thromb Haemost 2006; 4:766-773.
10. Bowman M, Mundell G, Grabell J, et al. Generation and validation of the Condensed MCMDM-1VWD Bleeding Questionnaire for von Willebrand disease. J Thromb Haemost 2008; 6:2062-2066.
11. Biss TT, Blanchette VS, Clark DS, et al. Quantitation of bleeding symptoms in children with von Willebrand disease: use of a standardized pediatric bleeding questionnaire. J Thromb Haemost 2010; 8:950-956.
12. Rodeghiero F, Tosetto A, Abshire T, et al. ISTH/SSC bleeding assessment tool: a standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders. J Thromb Haemost 2010; 8:2063-2065.
13. Mauer AC, Khazanov NA, Levenkova N, et al. Impact of sex, age, race, ethnicity and aspirin use on bleeding symptoms in healthy adults. J Thromb Haemost 2011; 9:100-108.
14. Buchanan GR, Adix L. Grading of hemorrhage in children with idiopathic thrombocytopenic purpura. J Pediatr 2002; 141:683-688. (Pubitemid 35292768)
15. Bolton-Maggs PH, Moon I. Assessment of UK practice for management of acute childhood idiopathic thrombocytopenic purpura against published guidelines. Lancet 1997; 350:620-623. (Pubitemid 27367795)
16. Page LK, Psaila B, Provan D, et al. The immune thrombocytopenic purpura (ITP) bleeding score: assessment of bleeding in patients with ITP. Br J Haematol 2007; 138:245-248. (Pubitemid 46976321)
17. Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer 1981; 47:207-214. (Pubitemid 11167383)
18. Mehran R, Rao SV, Bhatt DL, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation 2011; 123:2736-2747.
19. Loewen P, Dahri K. Risk of bleeding with oral anticoagulants: an updated systematic review and performance analysis of clinical prediction rules. Ann Hematol 2011; 90:1191-1200.
20. Mauer AC, Barbour EM, Khazanov NA, et al. Creating an ontology-based human phenotyping system: the Rockefeller University bleeding history experience. Clin Translat Sci 2009; 2:382-385.
21. Reddy B, Pagel C, Vuylsteke A, et al. An operational research approach to identify cardiac surgery patients at risk of severe postoperative bleeding. Healthcare Manag Sci 2011; 14:215-222.
22. Sadler JE. Von Willebrand disease type 1: a diagnosis in search of a disease. Blood 2003; 101:2089-2093. (Pubitemid 36302041)
23. Sadler JE, Rodeghiero F. Provisional criteria for the diagnosis of VWD type 1. J Thromb Haemost 2005; 3:775-777. (Pubitemid 41647892)
24. Federici AB, Mannucci PM, Castaman G, et al. Clinical and molecular predictors of thrombocytopenia and risk of bleeding in patients with von Willebrand disease type 2B: a cohort study of 67 patients. Blood 2009; 113:526-534.
25. Biss TT, Blanchette VS, Clark DS, et al. Use of a quantitative pediatric bleeding questionnaire to assess mucocutaneous bleeding symptoms in children with a platelet function disorder. J Thromb Haemost 2010; 8:1416-1419.
26. Bowman M, Riddel J, Rand ML, et al. Evaluation of the diagnostic utility for von Willebrand disease of a pediatric bleeding questionnaire. J Thromb Haemost 2009; 7:1418-1421.
27. Marcus PD, Nire KG, Grooms L, et al. The power of a standardized bleeding score in diagnosing paediatric type 1 von Willebrand's disease and platelet function defects. Haemophilia 2011; 17:223-227.
28. Tosetto A, Castaman G, Plug I, et al. Prospective evaluation of the clinical utility of quantitative bleeding severity assessment in patients referred for hemostatic evaluation. J Thromb Haemost 2011; 9:1143-1148.
29. Sidonio RF, Gunawardena S, Shaw PH, Ragni M. Predictors of von Willebrand disease in children. Pediatr Blood Cancer 2012; 58:736-740.
30. Higham JM, O'Brien PM, Shaw RW. Assessment of menstrual blood loss using a pictorial chart. Br J Obstet Gynaecol 1990; 97:734-739. (Pubitemid 20263124)
31. Philipp CS, Faiz A, Dowling NF, et al. Development of a screening tool for identifying women with menorrhagia for hemostatic evaluation. Am J Obstet Gynecol 2008; 198:163-168.
32. Philipp CS, Faiz A, Heit JA, et al. Evaluation of a screening tool for bleeding disorders in a US multisite cohort of women with menorrhagia. Am J Obstet Gynecol 2011; 204:209-217.
33. McKay H, Derome F, Haq MA, et al. Bleeding risks associated with inheritance of the Quebec platelet disorder. Blood 2004; 104:159-165. (Pubitemid 38879852)
34. Bleeding History Phenotyping System Repository. 2012. https://bh.rockefel ler.edu/RUBHPSR. [Accessed 14 June 2012]
35. Bleeding History Phenotype. 2012. http://bioportal.bioontology.org/ontolo gies/1116. [Accessed 14 June 2012]
36. Bussel JB, Cheng G, Saleh MN, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med 2007; 357:2237-2247. (Pubitemid 350190754)
37. Bussel JB, Provan D, Shamsi T, et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial. Lancet 2009; 373:641-648.
38. Cheng G, Saleh MN, Marcher C, et al. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet 2011; 377:393-402.
39. Godeau B, Porcher R, Fain O, et al. Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study. Blood 2008; 112:999-1004.
40. Khellaf M, Michel M, Quittet P, et al. Romiplostim safety and efficacy for immune thrombocytopenia in clinical practice: 2-year results of 72 adults in a romiplostim compassionate-use program. Blood 2011; 118:4338-4345.
41. Mazzucconi MG, Fazi P, Bernasconi S, et al. Therapy with high-dose dexamethasone (HD-DXM) in previously untreated patients affected by idiopathic thrombocytopenic purpura: a GIMEMA experience. Blood 2007; 109:1401-1407. (Pubitemid 46239570)
42. Fogarty PF, Tarantino MD, Brainsky A, et al. Selective validation of the WHO Bleeding Scale in patients with chronic immune thrombocytopenia. Curr Med Res Opin 2012; 28:79-87.
43. Heddle NM, Cook RJ, Tinmouth A, et al. A randomized controlled trial comparing standard-and low-dose strategies for transfusion of platelets (SToP) to patients with thrombocytopenia. Blood 2009; 113:1564-1573.
44. McCullough J, Vesole DH, Benjamin RJ, et al. Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial. Blood 2004; 104:1534-1541. (Pubitemid 39166535)
45. Slichter SJ, Kaufman RM, Assmann SF, et al. Dose of prophylactic platelet transfusions and prevention of hemorrhage. N Engl J Med 2010; 362:600-613.
46. Webert K, Cook RJ, Sigouin CS, et al. The risk of bleeding in thrombocytopenic patients with acute myeloid leukemia. Haematologica 2006; 91:1530-1537. (Pubitemid 44736120)
47. Mamas MA, Ratib K, Routledge H, et al. Influence of access site selection on PCI-related adverse events in patients with STEMI: meta-analysis of randomised controlled trials. Heart 2012; 98:303-311.
48. Ndrepepa G, Schuster T, Hadamitzky M, et al. Validation of the Bleeding Academic Research Consortium definition of bleeding in patients with coronary artery disease undergoing percutaneous coronary intervention. Circulation 2012; 125:1424-1431.
49. Landefeld CS, Cook EF, Flatley M, et al. Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy. Am J Med 1987; 82:703-713.
50. Gage BF, Yan Y, Milligan PE, et al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J 2006; 151:713-719. (Pubitemid 43290267)
51. Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HASBLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010; 138:1093-1100.
52. Lip GY, Frison L, Halperin JL, et al. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. J Am Coll Cardiol 2011; 57:173-180.
53. Chen WT, White CM, Phung OJ, et al. Association between CHADS risk factors and anticoagulation-related bleeding: a systematic literature review. Mayo Clin Proc 2011; 86:509-521.
54. Oldgren J, Alings M, Darius H, et al. Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: a subgroup analysis of the RE-LY trial. Ann Intern Med 2011; 155:660-667; W204.
55. French D, Nurden A, Wilcox DA. Glanzmann Thrombasthenia Database. http://sinaicentral mssm edu/intranet/research/glanzmann/menu 2011. http://sinaicentral.mssm.edu/intranet/research/glanzmann/menu. [Accessed 14 June 2012]
56. Sadler JE. Low von Willebrand factor: sometimes a risk factor and sometimes a disease. Hematology Am Soc Hematol Educ Program 2009; 106-112.